Michael Hornsey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1911801/publications.pdf

Version: 2024-02-01

26 1,702 19 27 papers citations h-index 28 28 28 2371

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Phosphoethanolamine Modification of Lipid A in Colistin-Resistant Variants of Acinetobacter baumannii Mediated by the pmrAB Two-Component Regulatory System. Antimicrobial Agents and Chemotherapy, 2011, 55, 3370-3379.	3.2	354
2	A Novel Variant, NDM-5, of the New Delhi Metallo- \hat{l}^2 -Lactamase in a Multidrug-Resistant Escherichia coli ST648 Isolate Recovered from a Patient in the United Kingdom. Antimicrobial Agents and Chemotherapy, 2011, 55, 5952-5954.	3.2	312
3	AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2010, 65, 1589-1593.	3.0	129
4	Development and evaluation of a multiplex PCR for eight plasmid-mediated quinolone-resistance determinants. Journal of Medical Microbiology, 2013, 62, 1823-1827.	1.8	117
5	<i>In Vivo</i> Efficacy of Glycopeptide-Colistin Combination Therapies in a <i>Galleria mellonella</i> Model of <i>Acinetobacter baumannii</i> Infection. Antimicrobial Agents and Chemotherapy, 2011, 55, 3534-3537.	3.2	113
6	Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 1499-1503.	3.0	96
7	In vitro activity of teicoplanin combined with colistin versus multidrug-resistant strains of Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy, 2011, 66, 1047-1051.	3.0	74
8	<i>In Vitro</i> Activity of Telavancin in Combination with Colistin versus Gram-Negative Bacterial Pathogens. Antimicrobial Agents and Chemotherapy, 2012, 56, 3080-3085.	3.2	56
9	<i>In Vitro</i> and <i>In Vivo</i> Activities of Tigecycline-Colistin Combination Therapies against Carbapenem-Resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3541-3546.	3.2	50
10	Genetic characterization of tigecycline resistance in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes. Journal of Antimicrobial Chemotherapy, 2013, 68, 1011-1018.	3.0	48
11	Novel Antibacterials: Alternatives to Traditional Antibiotics. Advances in Microbial Physiology, 2018, 73, 123-169.	2.4	48
12	In vivo efficacy of telavancin/colistin combination therapy in a Galleria mellonella model of Acinetobacter baumannii infection. International Journal of Antimicrobial Agents, 2013, 41, 285-287.	2.5	42
13	Emergence of AcrAB-mediated tigecycline resistance in a clinical isolate of Enterobacter cloacae during ciprofloxacin treatment. International Journal of Antimicrobial Agents, 2010, 35, 478-481.	2.5	36
14	Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome. Journal of Antimicrobial Chemotherapy, 2010, 65, 479-482.	3.0	32
15	Deletions in a ribosomal protein-coding gene are associated with tigecycline resistance in Enterococcus faecium. International Journal of Antimicrobial Agents, 2015, 46, 572-575.	2.5	32
16	Evaluation of three selective chromogenic media, CHROMagar ESBL, CHROMagar CTX-M and CHROMagar KPC, for the detection ofKlebsiella pneumoniaeproducing OXA-48 carbapenemase: TableÂ1. Journal of Clinical Pathology, 2013, 66, 348-350.	2.0	27
17	In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. International Journal of Antimicrobial Agents, 2013, 42, 343-346.	2.5	25
18	In vitro and In vivo Activity of Theaflavin–Epicatechin Combinations versus Multidrug-Resistant Acinetobacter baumannii. Infectious Diseases and Therapy, 2017, 6, 435-442.	4.0	25

#	Article	IF	CITATIONS
19	In vitro activity of daptomycin in combination with low-dose colistin against a diverse collection of Gram-negative bacterial pathogens. European Journal of Clinical Microbiology and Infectious Diseases, 2013, 32, 1291-1294.	2.9	24
20	Restoring the activity of the antibiotic aztreonam using the polyphenol epigallocatechin gallate (EGCG) against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. Journal of Medical Microbiology, 2019, 68, 1552-1559.	1.8	20
21	Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections—authors' response. Journal of Antimicrobial Chemotherapy, 2020, 75, 2713-2713.	3.0	11
22	Effects of In vivo Emergent Tigecycline Resistance on the Pathogenic Potential of Acinetobacter baumannii. Scientific Reports, 2018, 8, 4234.	3.3	9
23	Characterization of a colistin-resistant Avian Pathogenic Escherichia coli ST69 isolate recovered from a broiler chicken in Germany. Journal of Medical Microbiology, 2019, 68, 111-114.	1.8	9
24	Cefepime/sulbactam as an enhanced antimicrobial combination therapy for the treatment of MDR Gram-negative infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 135-139.	3.0	4
25	P317 Isolation and characterisation of a novel Nesterenkonia species from a human bloodstream infection. International Journal of Antimicrobial Agents, 2013, 42, S141-S142.	2.5	2
26	De-escalation of antimicrobial therapy in Gram-negative sepsis: easier said than done?. Critical Care, 2011, 15, .	5.8	1